Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of GS1-144 in Healthy Volunteers and Postmenopausal Women
NCT06204250Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GS1-144 in vasomotor symptoms (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events. Started Feb 2024; status: completed.
02
Drugs
GS1-144
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06204250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06204250.